Urs Schwitter

USPTO Granted Patents = 20 (Patent Applications = 9)

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 10 (Patent Applications = 11)

Average Co-Inventor Count = 5.6

ph-index = 2

Forward Citations = 64(Granted Patents)

Location History:

Reinach BL, CH (2011 - 2019)
Reinach, CH (2007 - 2021)
Basel, CH (2017 - 2024)

Company Filing History:

18 out of 4,942

Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

patents

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

20 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12459947 - Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crystalline forms thereof (2025-11-04),

2. 12122789 - Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making (2024-10-22),

3. 12012421 - Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate (2024-06-18),

4. 12012420 - Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate (2024-06-18),

5. 11230559 - Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-Yl]proptl] acetate (2022-01-25),

6. 11040977 - Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[e]azulene and crytalline forms thereof (2021-06-22),

7. 10919041 - Preparing and analyzing solid form properties of a substance (2021-02-16),

8. 10246460 - Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10B-tetraaza-benzo[E]azulene and crytalline forms thereof (2019-04-02),

9. 10227298 - Solid forms of a pharmaceutically active compound (2019-03-12),

10. 10221125 - Solid forms (2019-03-05),

11. 9676793 - Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same (2017-06-13),

12. 9562009 - Process to manufacture N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxo-pyrrolidin-3-yl]acetamide (2017-02-07),

13. 8975397 - Solid forms (2015-03-10),

14. 8865735 - Solid forms of a pharmaceutically active substance (2014-10-21),

15. 8785435 - Solid forms (2014-07-22),

Title: **Urs Schwitter: Innovator in Pharmaceutical Chemistry**

Introduction

Urs Schwitter, a prominent inventor based in Reinach, Switzerland, has made significant contributions to the field of pharmaceutical chemistry, with a remarkable portfolio of 19 patents to his name. His innovative work primarily focuses on the development of novel compounds with potential therapeutic applications, particularly in the treatment of viral diseases.

Latest Patents

Among his latest patents, Urs Schwitter has developed processes and formulations for pyrido[1,2-a]pyrimidin-4-one derivatives. This invention pertains to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one, which is identified as a pharmaceutically active compound. Another significant patent includes the solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate. This invention discusses novel solid forms that may serve as TLR7 agonists, applicable in the treatment or prophylaxis of diseases caused by HBV infection.

Career Highlights

Throughout his career, Urs Schwitter has collaborated with well-known companies such as Hoffmann-La Roche Inc. and Plexxikon Inc. His expertise in pharmaceutical development has positioned him as a key player in the industry, driving forward innovations that have the potential to impact healthcare positively.

Collaborations

Urs has worked alongside notable professionals including Olaf Grassmann and Ralph Diodone. These collaborations have contributed to the dynamic exchange of ideas and advancements in their collective research endeavors.

Conclusion

Urs Schwitter continues to be a vital contributor to pharmaceutical science, leveraging his extensive knowledge and inventiveness to develop groundbreaking compounds. His patents reflect a commitment to addressing pressing health issues, ensuring that his work will leave a lasting impact on the field.

This text is generated by artificial intelligence and may not be accurate.